Neuroactive steroids, compositions, and uses thereof

Patent metadata

Field	Value
Publication number	US-12129275-B2
Application number	US-202217707303-A
Country	US
Kind code	B2
Filing date	Mar 29, 2022
Priority date	Sep 8, 2011
Publication date	Oct 29, 2024
Grant date	Oct 29, 2024

Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

First claim

What is claimed is:

1. A compound of Formula (I-b1), (I-b2) or (I-b3):

or a pharmaceutically acceptable salt thereof;
wherein:
Z is selected from the group consisting of

R 3b is hydrogen;
R 3a is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
each instance of R 2 , R 11a , and R 11b is independently hydrogen or —OR B1 , wherein R B1 is hydrogen or substituted or unsubstituted alkyl, or R 11a and R 11b are joined to form an oxo (═O) group; and
each of R 6a and R 6b is independently hydrogen, halo, or substituted or unsubstituted alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3a is substituted or unsubstituted alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein R 6b is halo or substituted or unsubstituted alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —OR B1 .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 11b is hydrogen or —OR B1 , and R 11a is hydrogen.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 11a and R 11b are joined to form an oxo group.

8. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

9. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

11. The compound of claim 8 , wherein the compound is selected from the group consisting of:

12. The compound of claim 9 , wherein the compound is selected from the group consisting of:

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 11 .

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 12 .

15. The compound of claim 8 , wherein the compound is a pharmaceutically acceptable salt of a compound selected from the group consisting of:

16. The compound of claim 9 , wherein the compound is a pharmaceutically acceptable salt of a compound selected from the group consisting of:

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 15 .

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 16 .

Assignees

• Sage Therapeutics Inc

Inventors

• Upasani Ravindra B
• Harrison Boyd L
• Askew Benny C
• Dodart Jean-Cosme
• Salituro Francesco G
• Robichaud Albert Jean

Classifications

• C07J1/00 Primary

  Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane · CPC title

• C07J75/00

  Processes for the preparation of steroids in general · CPC title

• C07J43/003

  not condensed · CPC title

• C07J41/0055

  the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives · CPC title

• C07J41/0011

  Unsubstituted amino radicals · CPC title